Industry News
Recent News:
September 9, 2026—Narcolepsy Network would like to share a press release that is posted on Takeda’s website. The press release is titled “New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life”
August 5, 2026—Narcolepsy Network would like to share a press release that is posted on Takeda’s website. The press release is titled “U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1”
May 12, 2026—Narcolepsy Network would like to share a press release that is posted on Alkermes’ website. The press release is titled “Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia.”
April 1, 2026—Narcolepsy Network would like to share a press release that is posted on Alkermes’ website. The press release is titled “Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2”
February 17, 2026—Narcolepsy Network would like to share a press release that is posted on Harmony Biosciences’ website. The press release is titled “Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy.”
February 10, 2026—Narcolepsy Network would like to share a press release that is posted on Takeda Pharmaceuticals’ website. The press release is titled “U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1.”
January 6, 2026—Narcolepsy Network would like to share a press release that is posted on Alkermes Pharmaceuticals’ website. The press release is titled “Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1.”
November 19, 2025—Narcolepsy Network would like to share a press release that is posted on Harmony Biosciences’ website. The press release is titled “Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence.”
November 12, 2025—Narcolepsy Network would like to share a press release that is posted on Alkermes’ website. The press release is titled “Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2.”
November 5, 2025—Narcolepsy Network would like to share a press release that is posted on Centessa Pharmaceuticals’ website. The press release is titled “Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program November 5, 2025.”
October 22, 2025—Narcolepsy Network would like to share a press release that is posted on Alkermes Pharmaceuticals’ website. The press release is titled “Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc.”
October 22, 2025—Narcolepsy Network would like to share a press release that is posted on Avadel Pharmaceuticals’ website. The press release is titled “Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc.”
September 22, 2025—Narcolepsy Network would like to share a press release that is posted on Jazz Pharmaceuticals’ website. The press release is titled “Jazz Pharmaceuticals Showcases Phase 4 Data Demonstrating Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Effects and Real-World Evidence at World Sleep and Psych Congresses.”
September 8, 2025—Narcolepsy Network would like to share a press release that is posted on Alkermes’ website. The press release is titled “Alkermes Presents Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025.”
September 8, 2025—Narcolepsy Network would like to share a press release that is posted on Takeda Pharmaceuticals’ website. The press release presents “Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025.”
September 3, 2025—Narcolepsy Network would like to share a press release that is posted on Avadel’s website. The press release is titled “Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd.”
August 5, 2025—Narcolepsy Network would like to share a press release that is posted on Harmony Biosciences website. The press release is titled “Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025.”
July 21, 2025—Narcolepsy Network would like to share a press release that is posted on Alkermes’ website. The press release is titled “Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1.”
July 14, 2025—Narcolepsy Network would like to share a press release that is posted on Takeda Pharmaceuticals’ website. The press release is titled “Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TK-861) in Narcolepsy Type 1.”
June 9, 2025—Narcolepsy Network would like to share a press release that is posted on Jazz Pharmaceuticals’ website. This press release is titled “Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025.“
May 29, 2025—Narcolepsy Network would like to share a press release that is posted on Jazz Pharmaceuticals’ website. This press release is titled “Jazz Pharmaceuticals to Present Expansive Research Demonstrating Comprehensive Treatment Benefits of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in Sleep Conditions and Associated Comorbidities at SLEEP 2025.“
May 14, 2025—Narcolepsy Network would like to share a press release that is posted on Takeda Pharmaceuticals’ website. The press release is titled “The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1.”
April 1, 2025—Narcolepsy Network would like to share a press release that is posted on Alkermes’ website. The press release is titled “Initiation of Vibrance-3 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Idiopathic Hypersomnia.”
